Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 397-401

  Shuen, Andrew Y ^a   Wong, Betty Y L ^b   Fu, Lei ^a,b   Selby, Rita ^a,b   Cole, David E C ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Association studies; CYP2C9; Dosage algorithm; Genetic determinants; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ALGORITHM; ARTICLE; CALU GENE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SENSITIVITY; EPHX GENE; ETHNICITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; GGCX GENE; HAPLOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

AMINO ACID SUBSTITUTION; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DNA MUTATIONAL ANALYSIS; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MIXED FUNCTION OXYGENASES; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; WARFARIN;

EID: 84858382877     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.002     Document Type: Article

References (26)

1. Kamali F., Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010, 61:63-75.
2. Li T., Chang C.-Y., Jin D.-Y., Lin P.-J., Khvorova A., Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 2004, 427:541-544.
3. Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004, 427:537-541.
4. Wajih N., Sane D.C., Hutson S.M., Wallin R. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem 2004, 279:25276-25283.
5. Cain D., Hutson S.M., Wallin R. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 1997, 272:29068-29075.
6. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005, 5:262-270.
7. Wadelius M., Chen L.Y., Eriksson N., et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007, 121:23-34.
8. Pautas E., Moreau C., Gouin-Thibault I., et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010, 87:57-64.
9. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
10. Carlquist J.F., Horne B.D., Mower C., et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis 2010, 30:358-364.
11. Ciccacci C., Paolillo N., Di Fusco D., Novelli G., Borgiani P. EPHX1 polymorphisms are not associated with warfarin response in an Italian population. Clin Pharmacol Ther 2011, 89:791.
12. Moridani M., Fu L., Selby R., et al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin Biochem 2006, 39:606-612.
13. Sconce E.A. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
14. Gage B., Eby C., Johnson J., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331.
15. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
16. International Warfarin Pharmacogenetics Consortium Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
17. You J.H.S., Wong R.S.M., Waye M.M.Y., et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2010, 31:113-118.
18. Schelleman H., Chen J., Chen Z., et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008, 84:332-339.
19. Ross K.A., Bigham A.W., Edwards M., Gozdzik A., Suarez-Kurtz G., Parra E.J. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010, 55:582-589.
20. Limdi N.A., Wadelius M., Cavallari L., et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010, 115:3827-3834.
21. Rubin L.A., Hawker G.A., Peltekova V.D., Fielding L.J., Ridout R., Cole D.E. Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort. J Bone Miner Res 1999, 14:633-643.
22. Scott S.A., Edelmann L., Kornreich R., Desnick R.J. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008, 82:495-500.
23. Bodin L., Perdu J., Diry M., Horellou M.-H., Loriot M.-A. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008, 6:1436-1439.
24. Aklillu E., Leong C., Loebstein R., Halkin H., Gak E. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 2008, 111:3903-3904.
25. Loebstein R., Dvoskin I., Halkin H., et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007, 109:2477-2480.
26. Watzka M., Geisen C., Bevans C.G., et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 2011, 9:109-118.